Combination of Immunotherapy and Photo-pyroptosis as Novel Anticancer Strategy

Chembiochem. 2022 Aug 3;23(15):e202200201. doi: 10.1002/cbic.202200201. Epub 2022 May 6.

Abstract

Immunotherapy has made great progress in clinical cancer treatment in recent years, but its therapeutic efficacy is significantly limited by the lack of immunogenicity in the tumor microenvironment. Pyroptosis is a type of programmed cell death in which the dying cancer cells produce inflammatory cytokines to relieve the immuno-suppressive microenvironment and thus increase anti-tumor immunity. Reactive oxygen species (ROS) produced during photodynamic therapy (PDT) are one of the efficient activators that induce pyroptosis. Recently, a few photosensitizers have emerged with the ability to induce immunogenic cancer cell death via pyroptosis, opening a new field for PDT. This highlight introduces the latest research on antitumor strategies achieved by the combination of immunotherapy and photodynamic therapy through photo-pyroptosis.

Keywords: anticancer strategy; immunotherapy; photo-pyroptosis; photodynamic therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Humans
  • Immunotherapy
  • Neoplasms* / drug therapy
  • Photochemotherapy*
  • Photosensitizing Agents / pharmacology
  • Photosensitizing Agents / therapeutic use
  • Pyroptosis
  • Tumor Microenvironment

Substances

  • Photosensitizing Agents